Enhanced and complementary benefits of a nalfurafine and fingolimod combination to treat immune-driven demyelination.

Katharina RobichonRabia BibiMackenzie KiernanLisa DennyThomas E PrisinzanoBronwyn M KivellAnne Camille La Flamme

Published in: Clinical & translational immunology (2023)

This study indicates that KOR agonists can be used in combination with fingolimod and dimethyl fumarate with the nalfurafine-fingolimod combination providing enhanced benefits.

Keyphrases

multiple sclerosis